Annual Reports in Medicinal Chemistry, Volume 37

I. CENTRAL NERVOUS SYSTEM DISEASES

Section Editor: David W. Robertson, Pfizer Global Research & Development, Ann Arbor, MI

1. Promise and Progress of Central G-Protein Coupled Receptor Modulators 1 for Obesity Treatments Brian L. Largent, Albert J. Robichaud and Keith J. Miller, Bristol-Myers Squibb Company, Wilmington, Delaware

1. Attention Deficit Hyperactivity Disorder: Pathophysiology and Design of 11 New Treatments Shelly A. Glase, Larry D. Wise and David W. Robertson, Pfizer Global Research and Development, Ann Arbor, Michigan

1. 5-HT2C Receptor Modulators: Progress in Development of 21 New CNS Medicines
   Larry E. Fitzgerald and Michael D. Ennis, Pharmacia Corporation, Kalamazoo, Michigan

1. Emerging Themes in Alzheimer's Disease Research: Paradigm Shift in Drug Discovery 31 Todd Morgan, School of Gerontology, University of Southern California, Los Angeles, California and Grant A. Krafft, Acumen Pharmaceuticals, Glenview, Illinois

II. CARDIOVASCULAR AND PULMONARY DISEASES

Section Editor: William J. Greenlee, Schering-Plough Research Institute, Kenilworth, New Jersey

1. Recent Advances in Pulmonary Hypertension Therapy 41
   Russell A. Bialecki, AstraZeneca Pharmaceuticals, Wilmington, Delaware

1. Phosphodiesterase 5 Inhibitors 53
   Andrew W. Stamford, Schering-Plough Research Institute, Kenilworth, New Jersey

1. Antagonists of VLA-4 65
   George W. Holland, Ronald J. Biediger, and Peter Vanderslice, Texas Biotechnology Corporation, Houston, Texas

1. Purine and Pyrimidine Nucleotide (P2) Receptors 75 Kenneth A. Jacobson, Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland

1. Anticoagulants: Inhibitors of the Factor VIIa/ Tissue Factor Pathway 85
   Leslie A. Robinson and Eddine M. K. Saiah, Deltagen Research Laboratories, San Diego, California

III. CANCER AND INFECTIOUS DISEASES

Section Editor: Jacob J. Plattner, Chiron Corporation, Emeryville, California

1. The Prospect for Microbial Genomics Providing Novel, Exploitable, 95 Antibacterial Targets
   Thomas J. Dougherty, Pfizer Global Research & Development, Groton, Connecticut and John F. Barrett, Merck Research Laboratories, Rahway, New Jersey

2. The Chemistry and Biology of Tetracyclines 105
   Mark L. Nelson, Paratek Pharmaceuticals, Inc., Boston, Massachusetts

1. Intracellular Signaling Targets for Cancer Chemosensitization 115
   Thomas G. Gesner and Stephen D. Harrison, Chiron Corporation, Emeryville, California

1. Emerging Microtubule Stabilizing Agents for Cancer Chemotherapy 125
   David C. Myles, Kosan Biosciences, Inc., Hayward, California

1. Antiviral Agents 133 Nicholas A. Meanwell, John F. Kadow and Paul M. Scola, The Bristol-Myers Squibb Pharmaceutical Research Institute Wallingford, Connecticut

1. Aerosol Delivery of Antibiotics 149
   Peter B. Challoner, Chiron Corporation, Emeryville, California

IV. IMMUNOLOGY, ENDOCRINOLOGY AND METABOLIC DISEASES

Section Editor: William K. Hagmann, Merck Research Laboratories, Rahway, New Jersey

1. Therapeutic Applications of Non-peptidic d-Opioid Agonists 159
   Graham N. Maw and Donald S. Middleton, Pfizer Global Research and Development, Department of Discovery Chemistry, Sandwich, Kent

1. Selective Glucocorticoid Receptor Modulators 167
   Michael J. Coghlan, Steven W. Elmore†, Philip R. Kym† and Michael E. Kort†, Eli Lilly and Company, Discovery Chemistry Research & Technologies, DC , †Lilly Corporate Center, Indianapolis, Indiana, Abbott Laboratories, Global Pharmaceutical Research and Development, Illinois

1. Inhibitors of p38 a MAP Kinase 177
   Sarvajit Chakravarty and Sundeep Dugar, Scios Inc. Sunnyvale, California

V. TOPICS IN BIOLOGY

Section Editor: Janet M. Allen, Inpharmatica, London, United Kingdom

1. Expanding and Exploring Cellular Pathways for Novel Drug Targets 187 Malcolm P. Weir, John P. Overington and Marlon Schwarz, Inpharmatica Ltd., London,

1. Searching for Alzheimer's Disease Therapies In Your Medicine Cabinet: 197 The Epidemiological and Mechanistic Case For NSAIDs and Statins Robert B. Nelson, Pfizer Global Research and Development, Groton, Connecticut

1. Matrix Metalloproteinases and the Potential Therapeutic Role for Matrix 209
   Metalloproteinase Inhibitors in Chronic Obstructive Pulmonary Disease Kevin M. Bottomley and Maria G. Belvisi, Inpharmatica, London and Respiratory Pharmacology, Cardiothoracic Surgery, Imperial College School of Medicine, National Heart and Lung Institute, London

1. Fc Receptor Structure and the Design of Anti-inflammatories: New 217 Therapeutics For Autoimmune Disease. Geoffrey A. Pietersz, Maree S. Powell, Paul A. Ramsland and P. Mark Hogarth, Austin Research Institute, Austin and Repatriation Medical Center, Victoria, Australia

1. Tumor classification for tailored cancer therapy 225 Fiona McLaughlin and Nick LaThangue, Prolifix Ltd, Abingdon, Oxon

VI. TOPICS IN DRUG DESIGN AND DISCOVERY

Section Editor: George L. Trainor, DuPont Pharmaceuticals Company, Wilmington, Delaware

1. Advances in the Discovery and Characterization of Ion Channel 237
   Modulators: Focus on Potassium Channels
   Valentin K. Gribkoff and John E. Starrett, Jr., Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut
2. Microwave-Assisted Chemistry as a Tool for Drug Discovery 247
   Carolyn D. Dzierba and Andrew P. Combs, Bristol-Myers Squibb Co. Experimental Station, Wilmington, Delaware

VII. TRENDS AND PERSPECTIVES

Section Editor: Annette M. Doherty, Pfizer Global Research & Development, Fresnes Laboratories, Fresnes, France

1. To Market, To Market - 2001 257
   Patrick Bernardelli, Bernard Gaudillière and Fabrice Vergne, Pfizer Global Research & Development, Fresnes Laboratories, Fresnes, France

1. Biosimulation: Dynamic Modeling of Biological Systems 279
   Kevin Hall, Rebecca Baillie, and Seth Michelson, Entelos Inc., Menlo Park, California

COMPOUND NAME, CODE NUMBER AND SUBJECT INDEX, VOLUME 37 289

CUMULATIVE CHAPTER TITLES KEYWORD INDEX, VOLUMES 1-37 297

CUMULATIVE NCE INTRODUCTION INDEX, 1983-2001 315

CUMULATIVE NCE INTRODUCTION INDEX, 1983-2001, BY INDICATION 331

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.

Medicinal, pharmaceutical, and organic chemists.